Dova Pharmaceuticals (Dova Pharmaceuticals) Debt-to-Equity : 0.97 (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Debt-to-Equity?

Dova Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $2.25 Mil. Dova Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $30.05 Mil. Dova Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $33.24 Mil. Dova Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2019 was 0.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dova Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

DOVA's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Dova Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Dova Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Debt-to-Equity Chart

Dova Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Debt-to-Equity

2.01

0.49

0.27

Dova Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Debt-to-Equity	Get a 7-Day Free Trial									0.22	0.27	0.36	0.44	0.97

Competitive Comparison of Dova Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Dova Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dova Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dova Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dova Pharmaceuticals's Debt-to-Equity falls into.

Dova Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dova Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.667	+	13.941)	/	76.358
	=	0.27

Dova Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.251	+	30.047)	/	33.238
	=	0.97

Dova Pharmaceuticals (NAS:DOVA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dova Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707

Website

http://www.dova.com

Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.

Executives

Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd	officer: Chief Medical Officer	C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs	director
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli	director, officer: President & CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir	director, officer: President & CEO	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707